AVEO Oncology (AVEO) Prices 6M Share Common Offering at $8/Sh

Pre-Open Movers 03/23: (ORMP) (TKAT) (BLFS) Higher; (FREQ) (ANIX) (IONX) Lower (more...)

Today's Pre-Open Stock Movers

Frequency Therapeutics, Inc. (Nasdaq: FREQ) 72.4% LOWER; announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. Frequency also announced new data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The Company plans to advance further development of FX-322 as a... More

After-Hours Stock Movers 03/22: (BLFS) (CHMA) (PTGX) Higher; (IONS) (RAVN) (QS) Lower (more...)

Today's After-Hours Stock Movers

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) 19.4% LOWER; announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study... More

AVEO Oncology (AVEO) Announces 5M Share Proposed Public Offering of Common Stock

AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares... More

AVEO Oncology (AVEO) Announces U.S. Commercial Availability of FOTIVDA for Treatment of Adult Patients With R/R Advanced RCC Ahead of Previous Guidance

AVEO Oncology (Nasdaq: AVEO) today announced that FOTIVDA® (tivozanib) is now commercially available in the United States (U.S.) ahead of the previous March 31, 2021 guidance. On March 10, 2021, the U.S. Food and Drug Administration (FDA) approved FOTIVDA for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

We are thrilled to begin bringing FOTIVDA to patients battling relapsed or refractory kidney cancer, said Michael Bailey, president and chief... More